BioSight
Companies
Ceribell, Inc. logo

CBLL

NASDAQSUNNYVALE, CA
Ceribell, Inc.

Ceribell, Inc. is a medical technology company that has developed and commercialized the Ceribell System, a point-of-care EEG platform designed for rapid diagnosis and continuous monitoring of seizures in acute care settings. The system combines portable hardware with AI-powered algorithms to enable faster seizure detection than conventional EEG systems, which require specialized technicians and neurologists and suffer from significant diagnostic delays. As of December 31, 2025, the Ceribell System has been adopted by more than 600 hospitals across academic centers and community hospitals.

Price history not yet available for CBLL.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar